Skip to main content

Decheng Reports a Big ALPN Buy

November 15, 2023

From the Desk of Steve Strazza and Alfonso Depablos

Today’s most significant insider transaction comes in a Form 4 filing by Decheng Capital Management, a hedge fund focused on investing in early-stage life science companies.

Decheng reported a purchase in the biotech company Alpine Immune Sciences $ALPN worth more than $4.6 million.

Here’s The Hot Corner, with data through November 14, 2023:

In another Form 4, Broadwood Partners reported a $1.1 million purchase in medical device company STAAR Surgical $STAA.

Aside from institutional buying, there was also some notable activity from company executives. 

The Custom Truck One Source $CTOS CFO reported a purchase of $340,000, while the CEO of Pebblebrook Hotel $PEB filed for a $208,000 buy.

There was no significant options flow to report.

Stay tuned. We'll be back on Thursday with more insider activity.

If you want these insider transactions e-mailed to you every morning, click here to sign up for The Hot Corner.

And please reach out with any questions. We love hearing from you!

All Star Charts Team